Cross-Sector entity
Weiss Ratings is the most frequent co-covered peer, appearing in 7 of the 7 tracked stories. That works out to roughly 2.6 stories per week across a 19-day span. The busiest single day carried 3. Coverage clusters in earnings, which accounts for 2 of those 7, with the remainder spread across 3 other categories.
7 verified stories tracked
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 7 of the 7 tracked stories. That works out to roughly 2.6 stories per week across a 19-day span. The busiest single day carried 3. Coverage clusters in earnings, which accounts for 2 of those 7, with the remainder spread across 3 other categories. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each. We currently track 7 Cross-Sector stories that mention B. Riley Financial, published between July 31, 2026 and August 18, 2026.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering B. Riley Financial. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
B. Riley trims BRSP target
B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
JonesTrading reiterates BRSP buy
JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital.
BrightSpire reports Q2 earnings
BRSP posted EPS of $0.13, missing the $0.15 consensus, with revenue of $48.70 million.
James Frew buys AMPY shares
Insider James Frew acquired 25,000 Amplify Energy shares at an average cost of $3.95 per share.
Weiss lowers BrightSpire Capital
Weiss Ratings lowered BRSP from hold (c-) to sell (d+).
BTIG upgrades BrightSpire Capital
BTIG Research raised BRSP from neutral to buy and set a $7.00 price target.
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
Crocs, Inc. issued Q3 2026 guidance below expectations, with EPS of $3.20-$3.30 and revenue of $996.3 million, missing the consensus of $3.55 and $1.0 billion, respectively. The shortfall triggered a 7.4% stock decline, raising concerns about softening consumer demand for casual footwear heading into the back-to-school season.
AXT blew past Q3 consensus with EPS guidance of $0.30-$0.32 vs. $0.10 and revenue of $66M vs. $38.7M, while Crocs missed with $3.20-$3.30 EPS vs. $3.55 and $996.3M revenue vs. $1.0B. The split paints a complex picture for investors, highlighting a semiconductor super-cycle amid softening consumer discretionary.
Source: MarketBeat · themarketsdaily.com
